Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

Abstract

SummaryIn a double-blind comparative trial of sulpiride (600–1,800 mg/day) and trifluoperazine (15–45 mg/day) in 38 chronic schizophrenic patients, ratings of therapeutic results and unwanted effects were made at two-weekly interviews during the six weeks treatment period. The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine. There was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment.